Johnson & Johnson (JNJ) vs JPMorgan Chase & Co. (JPM)
See how Johnson & Johnson and JPMorgan Chase & Co. differ across market data and performance, so you can decide which asset best fits your strategy.
$253.04
NYSE
Johnson & Johnson is the world’s largest and most diversified healthcare company. Its operations are organized into two segments: Innovative Medicine and MedTech, which together account for all revenue following the 2023 separation of its consumer health business, Kenvue. After restructurings completed in 2023 and 2024, the pharmaceutical segment is focused on three core therapeutic areas: immunology, oncology, and neurology. From a geographic perspective, slightly more than half of the company’s total revenue comes from the United States.
JPMorgan Chase & Co. is a leading global financial services company operating in 66 countries with more than 318,000 employees as of year-end 2025. Through its JPMorgan brands, the bank holding company reported a $4.9 trillion balance sheet and $2.68 trillion in deposits as of March 2026. Revenue is generated across three main business segments: Consumer & Community Banking, Commercial & Investment Bank, and Asset & Wealth Management. The firm holds the top global position in investment banking fees with an 8.4% market share, serves millions of customers through more than 5,000 U.S. branches, and oversees over $7.1 trillion in client assets in its wealth and asset management business.